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AbstrAct
Objective To investigate sex differences in survival of 
primary care treated patients with type 2 diabetes (T2D) in 
the Netherlands.
setting Primary care.
Participants A total of 1815 patients who participated 
in a prospective observational cohort study (Zwolle 
Outpatient Diabetes Project Integrating Available Care 
(ZODIAC)) were included of which 56% was female. 
Inclusion took place in 1998, 1999 and 2001. Vital status 
was assessed in 2013.
Main outcome measure Relative survival of men and 
women with T2D. The relative survival rate was expressed 
as the ratio of observed survival of patients divided by the 
survival of the general population in the Netherlands with 
comparable age.
results After 14 years, 888 (49%) patients had died. The 
relative survival rate was 0.88 (0.81–0.94) for men and 
0.82 (0.76–0.87) for women with T2D after 14 years (p 
value for difference between sexes=0.169). In patients 
without a history of cardiovascular diseases (CVD), the 
relative survival was 0.99 (0.94–1.05) in men and 0.92 
(0.87–0.97) in women (p value for difference between 
sexes=0.046).
conclusions The survival of men and women with T2D 
was 12% and 18% lower, respectively, after 14 years 
of follow-up compared with men and women in the 
general population. This corresponds to a decrease in 
median survival of 2.2 and 3.5 years in men and women, 
respectively. Only for patients with T2D without a history 
of CVD, a significantly lower relative survival in women 
compared with men with T2D was found. 
IntrOductIOn
Mortality rates in patients with type 2 diabetes 
(T2D) are higher compared with the general 
population, which is predominantly caused 
by a higher occurrence of cardiovascular 
diseases (CVD) in patients with T2D.1–3 This 
excess mortality rate is described to be more 
pronounced in women compared with men 
with T2D.2–5 In a recent meta-analysis, the 
relative risk for mortality of incident coronary 
heart disease was 2.8 in women and 2.0 in 
men compared with men and women without 
diabetes, respectively.2
Current knowledge on sex differences in 
mortality is mostly based on older cohort 
studies. Whether these results are still 
reflecting current practice is less clear, as the 
care for patients with T2D has significantly 
improved over the last years.6 In the Nether-
lands, most patients with T2D receive proto-
col-based treatment exclusively in primary 
care. The mortality in this population is low, 
which is probably the result of a general 
improvement in quality of diabetes care 
over the last years.7 It is less well established 
whether sex differences in mortality also exist 
in well-controlled primary care patients. Only 
a few studies have been recently conducted 
in countries with a comparable care system 
to the Netherlands.8–10 A study from Norway 
also described a more pronounced excess 
mortality rate in women with T2D; however, 
this study also included secondary care 
treated patients.10 A retrospective study from 
the UK in primary care found only a slightly 
higher HR for all-cause mortality in women 
than in men with T2D, when compared with 
non-diabetics.8
The aim of this study was to investigate the 
survival of prospectively followed men and 
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Research
strengths and limitations of this study
 ► This study provides insight in the current situation 
concerning the survival of men and women with 
type 2 diabetes who are treated in primary care in 
the Netherlands.
 ► This study used the technique of relative survival 
analysis, hereby a comparison between the survival 
of patients with type 2 diabetes and the expected 
survival of whole general population could be made.
 ► The survival rates of men and women in the general 
population were derived from mortality rates of the 
entire nation.
 ► The generalisability is limited to primary care.
 ► No data were known concerning clinical variables in 
the general population, and therefore the results of 
the subgroups should be interpreted with caution.
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women with T2D, treated in primary care, compared with 
men and women in the general population.
MAterIAls And MethOds
study population and design
The study population consisted of patients who were 
included in the Zwolle Outpatient Diabetes Project 
Integrating Available Care (ZODIAC) study. This study 
was initiated in 1998, in the Zwolle region of the Neth-
erlands. The design and details of this study have been 
published previously.11 In this study, general practitioners 
were assisted by hospital-based diabetes specialist nurses 
in their care of patients with T2D. In the first year, 1143 
patients with T2D were included in this prospective cohort 
study. Another 127 and 545 patients with T2D entered 
this study in 1999 and 2001 respectively, resulting in a 
combined cohort of 1815 patients. All patients with T2D 
were selected from general practices in Zwolle region 
of the Netherlands. Patients with a very short life expec-
tancy or insufficient cognitive capabilities were excluded 
from participation as the care for these patients has not 
been delegated to diabetes specialist nurses. Whether 
the life expectancy was long enough to be included in 
the ZODIAC study was based on the judgement of the 
general practitioners.
The survival of this cohort was compared with the 
expected survival of men and women with the same age 
from the general population in the Netherlands. These 
expected survival rates were derived from data provided 
by Statistics Netherlands. This organisation provides 
survival rates for men and women of every age in the 
Netherlands.12
This study was approved by the local ethical committee 
of Isala, Zwolle, the Netherlands. All patients gave written 
informed consent.
data collection and measurements
Before participating in the ZODIAC study, T2D was 
already diagnosed in all individuals by their general prac-
titioners based on the guidelines of the Dutch College of 
General Practitioners (two times a fasting plasma glucose 
level ≥7 mmol/L or one time a non-fasting plasma 
glucose level ≥11.1 mmol/L accompanied by symptoms 
of hyperglycaemia).13
Information on CVD, smoking and medication use was 
collected during the check-up of the patient by the general 
practitioner or practice nurse at baseline of the study. 
Patients were considered to have a history of CVD if a 
history of angina pectoris, myocardial infarction, percuta-
neous transluminal coronary angioplasty, coronary artery 
bypass grafting, stroke or a transient ischaemic attack was 
documented in the patient record of the general practice. 
Data on heart failure were not collected as these were not 
properly documented at baseline. Smoking was included 
in the analyses as a categorical variable (yes/no). Labora-
tory and physical assessment data were collected at base-
line during the annual check-up of the patients by their 
general practitioner and practice nurse and included 
non-fasting lipid profile, glycated haemoglobin (HbA1c), 
serum creatinine, urinary albumin-to-creatinine ratio 
(ACR), blood pressure and information about neurop-
athy and diabetic retinopathy. ACR was measured using 
immunonephelometry (Behring Nephelometer, Mann-
heim, Germany), and blood pressure was measured twice 
with a Welch Allyn sphygmomanometer in the supine 
position after at least 5 min of rest. Foot sensibility was 
tested with 5.07 Semmes-Weinstein monofilaments. 
Neuropathy was defined as two or more errors in a test of 
three, at least at one foot. Diabetic retinopathy (DRP) was 
investigated with a retinal camera, and the fundus photos 
were judged by an ophthalmologist. Microalbuminuria 
was defined as an albumin-to-creatinine ratio between 
3.5 and 35 mg/mmol for women and between 2.5 and 
25 mg/mmol for men. Macroalbuminuria was defined as 
an albumin-to-creatinine ratio >35 mg/mmol for women 
and >25 mg/mmol for men. The same methods were 
used in each baseline year to measure the laboratory and 
physical assessment data.
clinical endpoints
The primary endpoint was the relative survival rate of 
men and women with T2D compared with the general 
population in the Netherlands. Secondary endpoints 
were the relative survival rates of patients with T2D in 
different subgroups, and the median survival of men 
and women. Subgroups for the relative survival analyses 
were defined for age (<60, 60–75 and >75 years), body 
mass index (BMI) (<25, 25–30 and >30 kg/m2), smoking, 
history of CVD, albuminuria (normoalbuminuria, micro-
albuminuria and macroalbuminuria), microvascular 
complications (defined as the presence of albuminuria, 
neuropathy or DRP) and for patients with a low CVD risk 
(defined as non-smoking patients without a history of CVD 
and microvascular complications). In 2013, vital status 
and cause of death of patients with T2D were retrieved 
from records maintained by the hospital and the general 
practitioners or from the nationwide Municipal Personal 
Records Database. Causes of death were coded according 
to the International Classification of Diseases, ninth revi-
sion (ICD-9). Cardiovascular death was defined as death 
in which the principal cause of death was cardiovascular 
in nature, using ICD-9 codes 390–459.
statistical analyses
Statistical analyses were performed using SPSS V.20.0 for 
Windows (SPSS) and Stata 14 (Stata). Baseline results 
were expressed as mean with SD or median with IQR for 
normally distributed and non-normally distributed data, 
respectively. Differences were considered to be signifi-
cant at a p value of <0.05. Survival was calculated using 
relative survival analysis.14 The relative survival rate was 
calculated by measuring the ratio of survival of patients 
observed in our ZODIAC cohort to the survival of men 
and women with corresponding age in the same base-
line year in the general population in the Netherlands. 
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Table 1 Baseline characteristics of the study population
Total (n=1815) Men (n=800) Women (n=1015) p Value
Age (years) 67.0 (±11.8) 65.0 (±11.8) 68.6 (±11.6) <0.001
Diabetes duration (years) 4.0 (2.0–9.0) 4.0 (1.8–9.0) 5.0 (2.0–10.0) 0.017
History of CVD 605 (33.3) 307 (38.4) 298 (29.4) <0.001
Smoking 342 (19.0) 206 (26.0) 136 (13.5) <0.001
BMI (kg/m2) 29.1 (±4.8) 28.2 (±4.1) 29.9 (±5.2) <0.001
SBP (mm Hg) 151.5 (±24.4) 147.2 (±23.4) 155.0 (±24.5) <0.001
HbA1c (mmol/mol) 7.0 (6.3–8.1) 6.9 (6.2–8.1) 7.1 (6.4–8.1) 0.131
Creatine (µmol/L) 92.0 (82.0–104.0) 98.0 (89.0–109.0) 86.0 (77.0–97.0) <0.001
Chol-HDL ratio 4.8 (3.9–5.9) 4.9 (4.0–6.0) 4.7 (3.8–5.8) 0.001
Retinopathy 190 (10.9) 70 (9.1) 120 (12.3) 0.030
Microalbuminuria 544 (30.8) 267 (34.0) 277 (28.3) 0.011
Macroalbuminuria 114 (6.5) 68 (8.7) 46 (4.7) 0.001
Neuropathy 477 (26.6) 212 (26.7) 265 (26.6) 0.931
Microvascular complications* 1012 (57.7) 466 (59.7) 546 (56.1) 0.120
Low CVD risk† 424 (23.4) 154 (19.3) 270 (26.6) <0.001
DM treatment
  Diet 318 (17.5) 158 (19.8) 160 (15.8) 0.026
  Oral only 1230 (67.8) 540 (67.6) 690 (68.0) 0.834
  Insulin 262 (14.5) 99 (12.4) 163 (16.1) 0.028
ACEi/ARB 433 (27.1) 179 (25.1) 254 (28.7) 0.108
Lipid-lowering drugs 278 (15.6) 139 (17.7) 139 (13.9) 0.030
Antiplatelet drugs 279 (15.6) 139 (17.6) 140 (14.0) 0.035
Death 888 (48.9) 381 (47.6) 507 (50.0) 0.325
CVD death 374 (20.6) 161 (20.1) 213 (21.0) 0.653
Values are depicted as n (%), mean (±SD) or median (IQR).
*Defined as the presence of albuminuria, neuropathy or DRP.
 †Defined as non-smoking patients without a history of CVD and microvascular complications.
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker.; BMI, body mass index; Chol-HDL, cholesterol-High Density Lipoprotein; CVD, 
cardiovascular disease; DM, diabetes mellitus; DRP, diabetic retinopathy; SBP, systolic blood pressure.
First, interval-specific and cumulative survival rates were 
measured for both the study population and the general 
population, using the Hakulinen method.15 The inter-
val-specific observed survival rate for each follow-up 
year of the study population was calculated based on the 
number of patients at risk, the number of deaths and the 
number of patients lost to follow-up in each year. The 
interval-specific expected survival rate for the general 
population was calculated using yearly specific survival 
data of the general population.12 Consequently, the cumu-
lative survival rate was measured for both the study group 
and the general population. Finally, the relative cumula-
tive survival rate was calculated. The relative cumulative 
survival rate for the total study population is described 
for each of the 14 follow-up years for men and women 
separately. To investigate whether the relative survival was 
significant different between sexes, the p value was calcu-
lated at 14 years of follow-up. For the subgroup analyses, 
the relative cumulative survival rate is only described after 
10 years of follow-up. Cumulative survival rates after 10 
years are described due to the fact that 14-year survival 
data were only available for patients who were included in 
1998. The relative cumulative survival rates after 10 years 
are therefore more reliable. p Values for the differences 
between sexes were calculated at 10 years of follow-up 
for the subgroup analyses. An estimation of the median 
survival of the study population was calculated using linear 
interpolation. For the general population, linear extrapo-
lation with the average difference between the cumulative 
survivals of the general population was conducted first, 
before using linear interpolation to estimate the median 
survival (see online supplementary file 1).
results
Baseline results of the study population are described in 
table 1. Fifty-six per cent of the patients were female. Mean 
age was 65.0 (11.8) years in men and 68.6 (11.6) years in 
women. The median diabetes duration was 4.0 (1.8–9.0) 
and 5.0 (2.0–10.0) years in men and women, respectively. 
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Men smoked more frequently and also had more often 
albuminuria and a previous history of CVD compared 
with women. Women had a higher systolic blood pressure, 
a higher BMI and more often diabetic retinopathy than 
men. Men were more often on diet treatment only while 
women were more often on insulin. Lipid-lowering drugs 
and antiplatelet drugs were more often used in men.
relative survival analyses
The incidence rate for all-cause mortality was 7.4 (6.7–
8.2) and 7.2 (6.5–7.8) per 100 person years in men and 
women with T2D, respectively. The incidence rate for 
CVD mortality was 3.1 (2.7–3.6) and 3.0 (2.6–3.4) per 100 
person years in men and women with T2D, respectively. 
The comparison between the survival of the patients with 
T2D and the general population is presented in table 2 
and figure 1 for men and women separately. After 14 
years, the relative survival rate was 0.88 (95%CI: 0.81 to 
0.94) for men and 0.82 (95%CI: 0.76 to 0.87) for women 
with T2D (p value for difference between sexes=0.169). 
The estimated median survival of men (mean age: 65.0) 
and women (mean age: 68.8) in the study population was 
13.8 and 13.0 years, respectively. In the general popula-
tion, the estimated median survival of men and women 
was 16.0 and 16.5 years respectively
subgroup analyses
The relative survival rate after 10 years for different 
subgroups is described in table 3 and figure 2 for men and 
women separately. In the subgroup of patients with T2D 
without microvascular complications, the relative survival 
rate of men and women with T2D was 1.01 (95%CI: 0.95 
to 1.07) and 0.98 (95%CI: 0.93 to 1.03), respectively 
(p=0.488). In patients with microvascular complications, 
the relative survival rate decreased to 0.82 (95%CI: 0.74 to 
0.89) for men and 0.77 (95%CI: 0.71 to 0.84) for women 
with T2D (p=0.395). In men and women with low CVD 
risk (defined as non-smoking patients without a history 
of CVD and microvascular complications) the relative 
survival rate was 1.08 (95%CI: 1.00 to 1.14) and 1.01 
(0.94–1.07), respectively (p=0.106). The relative survival 
rates of men<60 years, of men with a BMI between 25 and 
30 kg/m2, of men without a history of CVD and of men 
without albuminuria were not significantly different from 
men in the general population. The relative survival rate 
in women in all these categories was significantly lower 
compared with women in the general population. For 
patients without a history of CVD, the relative survival was 
significantly lower in women with T2D compared with 
men (p=0.046).
dIscussIOn
In primary care treated patients with T2D, the relative 
survival of men and women was 12% and 18% lower after 
14 years of follow-up compared with age-matched men 
and women in the general population, respectively. This 
translates into an overall decrease in median survival 
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Figure 1 Relative survival with 95% CI for men and women 
with type 2 diabetes. Men: blue line, women: red line.
of 2.2 years in men and 3.5 years in women with T2D 
compared with men and women in the general popula-
tion. Although the relative survival of women with T2D 
seems to be lower than in male counterparts, no signifi-
cant difference between sexes was found in the total study 
population. The survival rate in certain subgroups of men 
with T2D (young age, no albuminuria, no history of CVD, 
BMI 25–30) was comparable to the survival rate of men 
in the general population. In women, in these subgroups 
the relative survival was significantly lower compared with 
women without T2D. Only for patients with T2D without 
a history of CVD a significantly lower relative survival in 
women compared with men with T2D was found.
The differences in relative survival between men and 
women in the total study population could possibly be 
explained by both the higher age and longer diabetes dura-
tion in women with T2D. Although women have a lower 
relative survival, it is not significantly lower compared 
with men. When women would have the same age and 
the same diabetes duration as men, the difference in rela-
tive survival would likely be smaller. This strengthens our 
conclusion that in the total population there is no signif-
icant difference in relative survival between sexes. Many 
studies have described a higher excess mortality rate in 
women than in men with T2D.4 5 16 In our study, a higher 
impact of T2D in women was only found in the subgroup 
of patients without a history of CVD. In subgroups of 
patients<60 years of age, without albuminuria and with 
a BMI between 25 and 30 kg/m2, the relative survival of 
women with T2D was lower compared with women in the 
general population but not lower compared with the rela-
tive survival of men with T2D. The comparable survival 
of men with T2D without a history of CVD to men in the 
general population has partly been described before by 
Kalyani et al.17 In a population without ischaemic heart 
disease, they found an increased risk for the combined 
outcome of ischaemic heart disease and mortality in 
women with diabetes compared with women without 
diabetes whereas they found no differences in men.
The decrease in median survival which is found in our 
study seems to be smaller than those seen in previous 
studies. Results from the Framingham Heart Study 
showed that men and women with diabetes lived on 
average 7.5 (95% CI: 5.5 to 9.5) and 8.2 (95% CI: 6.1 to 
10.4) years less compared with men and women without 
diabetes. However, this cohort started between 1948 
and 1951 when treatment options for T2D were limited. 
In a more recent study from Canada, for both men and 
women at the age of 55 on average 5.0 (95% CI: 4.9 to 
5.1) and 6.0 (95% CI: 5.9 to 6.1) years lower life expec-
tancy was estimated compared with men and women 
without diabetes.18 Although patient characteristics 
differ between studies and various methods were used 
to measure survival, it may indicate that the loss of life 
years due to diabetes is decreasing in both men and 
women.
Although different theories have been described which 
may explain the observed sex difference in the impact 
of diabetes on survival, it is still not completely under-
stood. Undertreatment of women with T2D is mentioned 
as a possible explaining factor. A lower prescription 
percentage for aspirin and lipid-lowering drugs was found 
in women compared with men with T2D.19 However, in 
a recent study in primary care we did not find signifi-
cant sex differences in these prescribed medications.20 
The sex difference in survival may also be explained by 
a greater excess in cardiovascular risk factors between 
women with and without T2D compared with their male 
counterparts.4 21 This greater excess in risk factors is prob-
ably the result of a more favourable risk factor profile 
and a lower insulin resistance in women without diabetes 
compared with men.21 22 Although the relatively higher 
risk for women with T2D for fatal ischaemic heart disease 
remained significant in various meta-analyses after adjust-
ment for other cardiovascular risk factors, it may still be 
an explanation as only traditional risk factors were taken 
into account.2 4 The lower relative survival could also be 
a result of a higher prevalence of obesity in women with 
T2D. In the Netherlands, the prevalence of obesity is 
described to be 25% to 50% higher in women compared 
with men with T2D, whereas the prevalence of overweight 
is 20% to 35% higher in men compared with women in 
different age categories.20 Knowing that overweight is 
associated with a lower mortality risk and obesity with a 
higher mortality risk compared with patient with a normal 
weight, this could possibly be one of the explaining factors 
for the higher relative mortality rate in women with T2D.23 
Finally, the relative higher mortality in women with T2D 
may be a result of underdiagnosis of ischaemic heart 
disease in women. Women with T2D have less obstructive 
coronary disease compared with men, with higher rates 
of microvascular coronary dysfunction that may be more 
difficult to diagnose and treat.24 Also, a higher prevalence 
of undiagnosed heart failure with preserved ejection frac-
tion (HFpEF) is described in women compared with men 
with T2D.25 When focusing on the common symptoms 
and diagnostic criteria for ischaemic heart disease and 
HFpEF, these diagnoses could be easily missed in women. 
This may lead to undertreatment of women, resulting in 
a higher mortality when having T2D.
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Figure 2 Relative survival with 95% CI for men and women 
with type 2 diabetes after 10 years in different subgroups. 
Men: blue diamond, women: red square. BMI, body mass 
index; CVD, cardiovascular disease. *Defined as the absence 
of albuminuria, neuropathy and diabetic retinopathy; †defined 
as non-smoking patients without a history of CVD and 
microvascular complications. 
Some limitations should be mentioned. First, according 
to Hakulinen, relative survival is the ratio of the observed 
survival in a group of patients to the expected survival 
in a group of individuals in the general population, 
who are comparable with the patients concerning all 
possible factors affecting survival, except for the disease 
of interest.15 Our choice to compare survival of patients 
with T2D from the Zwolle region with the general popu-
lation can therefore be criticised. However, the under-
lying assumption by the use of the expected survivals of 
the general population is that the deaths directly due 
to T2D are a negligible proportion of all deaths in the 
general population. Second, although no specific indi-
cations exist which suggests that people in the Zwolle 
region are healthier or unhealthier compared with the 
whole population in the Netherlands, we do not now 
that for sure. It would have been better if we had used a 
control population from the Zwolle region, but unfortu-
nately such a control population was not available. Third, 
no data were known concerning clinical variables in the 
general population, as we did not used a specific control 
group but expected survival rates which were derived 
from mortality rates of the entire nation. Therefore, 
the results of the subgroups should be interpreted with 
caution. Fourth, the number of patients in subgroups was 
sometimes relatively low which has decreased the preci-
sion of the estimates. Fifth, selection bias has occurred in 
this study. The study population consisted only of patients 
with T2D who are treated in primary care. Patients in 
secondary care often have worse manifestations of T2D 
and more often macrovascular disease and will probably 
have a lower survival. Furthermore, patients with a very 
short life expectancy or insufficient cognitive capabilities 
were also excluded from participation. Although these 
limitations imply that the generalisability of our results 
is limited to primary care, it is still representative for a 
large part of the T2D population due to the fact that the 
majority (>85%) of the patients with T2D are treated 
in primary care in the Netherlands.26 In this group of 
patients with T2D, the survival is only 2.2 years lower in 
men and 3.5 years lower in women compared with men 
and women in the general population. In patients with 
T2D with no microvascular complication and in patients 
with a low-risk profile, even no difference in survival 
compared with the general population was found.
In conclusion, the relative survival in men and women 
with T2D compared with the general population was 
12% and 18% lower, respectively. The results of this study 
further show that survival in subgroups of men (ie, younger 
men, no albuminuria, no history CVD, BMI between 25 
and 30) is comparable to men in the general population, 
while the survival in women in these subgroups is still 
lower compared with women in the general population. 
Only in women with T2D without a history of CVD, the 
impact of diabetes on survival is higher compared with 
men with T2D.
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